The EoE-centered framework supports disease modeling, multidimensional efficacy endpoints, type 2 biomarker analysis, and cross-indication translational research
The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programs
The cost-effective platform delivers rapid pharmacological validation data in cynomolgus monkeys, helping biotech firms make confident R&D decisions before committing to full-scale IND studies.
